

From: [REDACTED] (SANTE)

Sent: 30 March 2017 22:42

To: [REDACTED] (SANTE)

Subject: FW: BTO about meeting N. Chaze with Bayer, 29 March 2017

I misspelled your name, sorry.

From: [REDACTED] (SANTE)

Sent: 30 March 2017 22:40

To: CHAZE Nathalie (CAB-ANDRIUKAITIS); JUELICHER Sabine (SANTE); MIKO Ladislav (SANCO)

Cc: (SANCO); (SANCO); (SANCO);

(SANCO); (SANTE); (SANCO); (SANTE);

(SANCO); (SANCO); (SANCO);

(SANTÉ);

Subject: BTO about meeting N. Chaze with Bayer, 29 March 2017

Participants

Bayer:

Commission

N. Chaze

Meeting was requested by Bayer, with objective to introduce new Head of Bayer office in Brussels, Mr Koch-Achelpöhler. A number of topics were raised:

1. Endocrine disruptors

Bayer considers technical amendment to annex as crucial, furthermore potency important. We urged them to reconsider position and to accept the proposed option based on WHO definition alone as this would address the current uncertainty due to the interim criteria. The derogation should be discussed at a later stage once criteria are adopted. NC stressed that derogation is an institutional issue for Parliament; this view is not shared by Bayer. Bayer would favour if COM could consider to open discussion on CMR as well in case derogation is discussed at a later stage.

2. NNI

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd

3. Import tolerances

4. Acquisition Monsanto

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd

